Current therapeutic options in retinopathy of prematurity;Aktuelle Therapieoptionen bei Frühgeborenenretinopathie

Ophthalmologe

Volumn 109, Issue 12, 2012, Pages 1189-1197

  Krohne, T U ^a   Aisenbrey, S ^b   Holz, F G ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bevacizumab; Laser photocoagulation; Ranibizumab; Retinopathy of prematurity; Vitrectomy

Indexed keywords

EID: 84871070335     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-012-2618-8     Document Type: Article

References (42)

1. Arevalo JF, Maia M, Flynn HW Jr et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213-216
2. Autrata R, Krejcirova I, Senkova K et al (2012) Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 22(5):687-694
3. Averbukh E (2005) The evidence supporting the early treatment for type 1 retinopathy of prematurity needs further evaluation. Arch Ophthalmol 123:406 (discussion 409-410)
4. Banach MJ, Ferrone PJ, Trese MT (2000) A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology 107:324-327 (discussion 328)
5. Carneiro AM, Costa R, Falcao MS et al (2012) Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90:e25-e30
6. Choi J, Kim JH, Kim SJ et al (2011) Long-term results of lens-sparing vitrectomy for stages 4B and 5 retinopathy of prematurity. Korean J Ophthalmol 25:305-310
7. Compernolle V, Brusselmans K, Acker T et al (2002) Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8:702-710
8. Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 106:471-479
9. Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft, Berufsverband der Augenärzte Deutschlands (2012) Stellungnahme zum Einsatz von Bevacizumab in der Therapie der Frühgeborenenretinopathie. Ophthalmologe 109:197-204
10. Early Treatment For Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684-1694
11. Engle WA (2004) Age terminology during the perinatal period. Pediatrics 114:1362-1364
12. European MAE (2007) Lucentis: scientific discussion (March 14, 2007). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000715/WC500043550.pdf (Zugegriffen: 21.10.2011)
13. Hairston RJ, Maguire AM, Vitale S et al (1997) Morphometric analysis of pars plana development in humans. Retina 17:135-138
14. Hardy RJ, Good WV, Dobson V et al (2004) Multicenter trial of early treatment for retinopathy of prematurity: study design. Control Clin Trials 25:311-325
15. Hartnett ME, Maguluri S, Thompson HW et al (2004) Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Retina 24:753-757
16. Hashimoto T, Zhang XM, Chen BY et al (2006) VEGF activates divergent intracellular signaling components to regulate retinal progenitor cell proliferation and neuronal differentiation. Development 133:2201-2210
17. Hinz BJ, Juan E de Jr, Repka MX (1998) Scleral buckling surgery for active stage 4A retinopathy of prematurity. Ophthalmology 105:1827-1830
18. Hoerster R, Muether P, Dahlke C et al (2012) Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol [Epub ahead of print]
19. Hu J, Blair MP, Shapiro MJ et al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000-1006
20. International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991-999
21. Jandeck C, Kellner U, Lorenz B et al (2008) Guidelines for ophthalmologic screening of premature infants. Ophthalmologe 105:955-963
22. Krohne TU, Eter N, Holz FG et al (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146:508-512
23. Krohne TU, Liu Z, Holz FG et al (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154:682-686
24. Laws DE, Haslett R, Ashby D et al (1994) Axial length biometry in infants with retinopathy of prematurity. Eye (Lond) 8(Pt 4):427-430
25. Lorenz B (2011) Kommentar: Anti-VEGF-Einsatz gut abwägen. Klin Monatsbl Augenheilkd 225:488-490
26. Lorenz B, Spasovska K, Elflein H et al (2009) Wide-field digital imaging based telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year results of a multicentre field study. Graefes Arch Clin Exp Ophthalmol 247:1251-1262
27. Lu JF, Bruno R, Eppler S et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779-786
28. Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388-1398
29. Matsuyama K, Ogata N, Matsuoka M et al (2010) Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 94:1215-1218
30. Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603-615
31. Moshfeghi DM, Berrocal AM (2011) Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology 118:1227-1228
32. Muether PS, Kribs A, Hahn M et al (2012) No advanced retinopathy of prematurity stages 4 or 5 in a large high-risk German cohort. Br J Ophthalmol 96:400-404
33. Ng EY, Connolly BP, McNamara JA et al (2002) A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 109:928-934 (discussion 935)
34. Palmer EA, Hardy RJ, Dobson V et al (2005) 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 123:311-318
35. Patel CK, Walker NJ, Kam JK (2010) A new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination. Br J Ophthalmol 94:1107-1109
36. Prenner JL, Capone A Jr, Trese MT (2004) Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Ophthalmology 111:2271-2273
37. Sato T, Wada K, Arahori H et al (2012) Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153:327-333
38. Sears JE, Sonnie C (2007) Anatomic success of lens-sparing vitrectomy with and without scleral buckle for stage 4 retinopathy of prematurity. Am J Ophthalmol 143:810-813
39. Section on Ophthalmology American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus (2006) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 117:572-576
40. Seiberth V, Linderkamp O, Vardarli I (1997) Transscleral vs transpupillary diode laser photocoagulation for the treatment of threshold retinopathy of prematurity. Arch Ophthalmol 115:1270-1275
41. Wilkinson AR, Haines L, Head K et al (2009) UK retinopathy of prematurity guideline. Eye (Lond) 23:2137-2139
42. Zepeda-Romero LC, Liera-Garcia JA, Gutierrez-Padilla JA et al (2010) Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye (Lond) 24:931-933